Martin H. Maurer

Martin H. Maurer

Auto-generated profile, based on publicly available information

Martin H. Maurer

Department of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ASArmin Schneider
Armin Schneider
CKCarola Krüger
Carola Krüger
TSTobias Steigleder
Tobias Steigleder
DWDaniela Weber
Daniela Weber
CPClaudia Pitzer
Claudia Pitzer
WSWolf-Rüdiger Schäbitz
Wolf-Rüdiger Schäbitz
G-CSF is a potent hematopoietic factor that enhances survival and drives differentiation of myeloid lineage cells, resulting in the generation of neutrophilic granulocytes. Here, we show that G-CSF passes the intact blood-brain barrier and reduces infarct volume in 2 different rat models of acute stroke. G-CSF displays strong antiapoptotic activity in mature neurons and activates multiple cell survival pathways. Both G-CSF and its receptor are widely expressed by neurons in the CNS, and their expression is induced by ischemia, which suggests an autocrine protective signaling mechanism. Surprisingly, the G-CSF receptor was also expressed by adult neural stem cells, and G-CSF induced neuronal differentiation in vitro. G-CSF markedly improved long-term behavioral outcome after cortical ischemia, while stimulating neural progenitor response in vivo, providing a link to functional recovery. Thus, G-CSF is an endogenous ligand in the CNS that has a dual activity beneficial both in counteracting acute neuronal degeneration and contributing to long-term plasticity after cerebral ischemia. We therefore propose G-CSF as a potential new drug for stroke and neurodegenerative diseases.

1 July 2002 in Stroke
Verified
Journal Article
Closed access
PDF file
KKKrisztian J. Kapinya
Krisztian J. Kapinya
DLDiana Löwl
Diana Löwl
CFCarsten Fütterer
Carsten Fütterer
MMMartin Maurer
Martin Maurer
KWKlaus F. Waschke
Klaus F. Waschke
UDUlrich Dirnagl
Ulrich Dirnagl
Background and Purpose — We tested whether volatile anesthetics induce neuroprotection that is maintained for a prolonged time. Methods — Rats were pretreated for 3 hours with 1 minimal anesthetic concentration of isoflurane or halothane in normal air (anesthetic preconditioning [AP]). The animals were subjected to permanent middle cerebral artery occlusion (MCAO) at 0, 12, 24, or 48 hours after AP. Halothane-pretreated animals were subjected to MCAO 24 hours after AP. Histological evaluation of infarct volumes was performed 4 days after MCAO. Cerebral glucose utilization was measured 24 hours after AP with isoflurane. Primary cortical neuronal cultures were exposed to 1.4% isoflurane for 3 hours. Oxygen-glucose deprivation (OGD) was performed 24 hours after AP. Injury was assessed 24 hours later by measuring the release of lactate dehydrogenase into the medium 24 hours after OGD. Results — Isoflurane anesthesia at 0, 12, and 24 hours before MCAO or halothane anesthesia 24 hours before MCAO significantly reduced infarct volumes (125±42 mm 3 , P =0.024; 118±51 mm 3 , P =0.008; 120±49 mm 3 , P =0.009; and 121±48 mm 3 , P =0.018, respectively) compared with control volumes (180±51 mm 3 ). Three hours of isoflurane anesthesia in rats did not have any effect on local or mean cerebral glucose utilization measured 24 hours later. Western blot analysis from cortical extracts of AP-treated animals revealed an increase of the inducible NO synthase (iNOS) protein beginning 6 hours after AP. The iNOS inhibitor aminoguanidine (200 mg/kg IP) eliminated the infarct-sparing effect of AP. In cultured cortical neurons, isoflurane exposure 24 hours before OGD decreased the OGD-induced release of lactate dehydrogenase by 49% ( P =0.002). Conclusions — Pretreatment with volatile anesthetics induces prolonged neuroprotection in vitro and in vivo, a process in which iNOS seems to be critically involved.

1 April 2006 in Experimental Hematology
Verified
Journal Article
Closed access
Wolfgang WagnerWolfgang Wagner
Wolfgang Wagner
RFRobert E. Feldmann
Robert E. Feldmann
ASAnja Seckinger
Anja Seckinger
MMMartin H. Maurer
Martin H. Maurer
FWFrederik Wein
Frederik Wein
AHAnthony D. Ho
Anthony D. Ho

31 December 2008 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
PDF file
DSDominik W Schelshorn
Dominik W Schelshorn
ASArmin Schneider
Armin Schneider
WKWolfgang Kuschinsky
Wolfgang Kuschinsky
DWDaniela Weber
Daniela Weber
CKCarola Krüger
Carola Krüger
MMMartin H Maurer
Martin H Maurer
Hemoglobin is the major protein in red blood cells and transports oxygen from the lungs to oxygen-demanding tissues, like the brain. Mechanisms that facilitate the uptake of oxygen in the vertebrate brain are unknown. In invertebrates, neuronal hemoglobin serves as intracellular storage molecule for oxygen. Here, we show by immunohistochemistry that hemoglobin is specifically expressed in neurons of the cortex, hippocampus, and cerebellum of the rodent brain, but not in astrocytes and oligodendrocytes. The neuronal hemoglobin distribution is distinct from the neuroglobin expression pattern on both cellular and subcellular levels. Probing for low oxygen levels in the tissue, we provide evidence that hemoglobin α-positive cells in direct neighborhood with hemoglobin α-negative cells display a better oxygenation than their neighbors and can be sharply distinguished from those. Neuronal hemoglobin expression is upregulated by injection or transgenic overexpression of erythropoietin and is accompanied by enhanced brain oxygenation under physiologic and hypoxic conditions. Thus we provide a novel mechanism for the neuroprotective actions of erythropoietin under ischemic—hypoxic conditions. We propose that neuronal hemoglobin expression is connected to facilitated oxygen uptake in neurons, and hemoglobin might serve as oxygen capacitator molecule.

22 September 2004 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
IPIoana Potrovita
Ioana Potrovita
WZWen Zhang
Wen Zhang
LBLinda Burkly
Linda Burkly
KHKyungmin Hahm
Kyungmin Hahm
JLJohn Lincecum
John Lincecum
MSMarkus Schwaninger
Markus Schwaninger
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor (TNF) family of cytokines. It has proangiogenic and proinflammatory propertiesin vivoand induces cell death in tumor cell lines. TWEAK effects are mediated by the membrane receptor Fn14. In a systematic search for genes regulated in a murine stroke model with the tag-sequencing technique massively parallel signature sequencing, we have identified TWEAK as an induced gene. After 24 hr of focal cerebral ischemiain vivoor oxygen glucose deprivation in primary cortical neurons, both TWEAK and its receptor Fn14 were significantly upregulated. TWEAK induced cell death in primary neurons. Transfection of a nuclear factor (NF)-κB-luciferase fusion gene demonstrated that TWEAK stimulated transcriptional activity of NF-κB through Fn14 and the IκB kinase. Inhibition of NF-κB reduced TWEAK-stimulated neuronal cell death, suggesting that NF-κB mediates TWEAK-induced neurodegeneration at least in part. Intraperitoneal injection of a neutralizing anti-TWEAK antibody significantly reduced the infarct size after 48 hr of permanent cerebral ischemia. In summary, our data show that TWEAK induces neuronal cell death and is involved in neurodegenerationin vivo.

1 July 2003 in Neuroscience Letters
Verified
Journal Article
Closed access
MMMartin H. Maurer
Martin H. Maurer
WTWolf K.C. Tripps
Wolf K.C. Tripps
RFRobert E. Feldmann
Robert E. Feldmann
WKWolfgang Kuschinsky
Wolfgang Kuschinsky